Literature DB >> 2941295

Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infection.

H J Peters.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2941295     DOI： 10.1007/bf02014003

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  2 in total

1.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

2.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191
  2 in total
  10 in total

1.  Comparison of three dosage regimens of ciprofloxacin in urinary tract infections.

Authors:  V Prát; M Horcicková; K Matousovic; M Hatala
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 2.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections.

Authors:  C Timmerman; I Hoepelman; J de Hond; T Boon; L Schreinemachers; H Mensink; J Verhoef
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

4.  Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections.

Authors:  H Lode; R Wiley; G Höffken; J Wagner; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 5.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.

Authors:  Culley Carson; Kurt G Naber
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 8.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.